NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Other Current Liabilities
NAYA Biosciences Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Other Current Liabilities
$3.4m
|
CAGR 3-Years
69%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Other Current Liabilities
$6.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
476%
|
CAGR 10-Years
82%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Current Liabilities
$1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Current Liabilities
$859m
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
6%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Current Liabilities
$1.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Current Liabilities
$522.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Other Current Liabilities?
Other Current Liabilities
3.4m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Other Current Liabilities amounts to 3.4m USD.
What is NAYA Biosciences Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
35%
Over the last year, the Other Current Liabilities growth was 875%. The average annual Other Current Liabilities growth rates for NAYA Biosciences Inc have been 69% over the past three years , 35% over the past five years .
You don't have any saved screeners yet